Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Baxalta Bails On Onconova After Phase III Study Launch

This article was originally published in Scrip

Executive Summary

Onconova Therapeutics Inc. said on March 3 that Baxalta US Inc. backed out of a deal to co-develop intravenous rigosertib three months after the companies began the Phase III INSPIRE clinical trial that will enroll 225 patients with high-risk myelodysplastic syndromes (HR-MDS).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC064673

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel